Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of HB-200 in Patients With Positive TTMV-HPV DNA After Definitive Treatment for HPV16 Positive HNSCC

Next Previous
X
Search
Trial Profile

Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of HB-200 in Patients With Positive TTMV-HPV DNA After Definitive Treatment for HPV16 Positive HNSCC

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HB 201 (Primary) ; HB 202 (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Mar 2025 Planned number of patients changed from 51 to 10.
    • 16 Jan 2025 Status changed from recruiting to active, no longer recruiting.
    • 30 Oct 2024 According to a HOOKIPA Pharma media release, company announced that researchers at Memorial Sloan Kettering Cancer Center (MSKCC) have dosed the first patients in an investigator initiated trial (IIT) of eseba-vec in patients with minimal residual disease positive (MRD+) HPV-driven head and neck cancer. Company expect initial safety and efficacy data from the IIT in 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top